EA200800281A1 - METHOD OF CORRECTION OF EXPERIMENTAL MYOCARDITIS WITH THE HELP OF INTERFERON ALPHA MICELLAR FORM - Google Patents

METHOD OF CORRECTION OF EXPERIMENTAL MYOCARDITIS WITH THE HELP OF INTERFERON ALPHA MICELLAR FORM

Info

Publication number
EA200800281A1
EA200800281A1 EA200800281A EA200800281A EA200800281A1 EA 200800281 A1 EA200800281 A1 EA 200800281A1 EA 200800281 A EA200800281 A EA 200800281A EA 200800281 A EA200800281 A EA 200800281A EA 200800281 A1 EA200800281 A1 EA 200800281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
interferon alpha
myocarditis
correction
help
micellar form
Prior art date
Application number
EA200800281A
Other languages
Russian (ru)
Other versions
EA015399B1 (en
Inventor
Алмагуль Тулеуовна Маншарипова
Алихан Казахпаевич Джусипов
Original Assignee
Ргкп Научно-Исследовательский Институт Кардиологии И Внутренних Болезней Министерства Здравоохранения Республики Казахстан
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ргкп Научно-Исследовательский Институт Кардиологии И Внутренних Болезней Министерства Здравоохранения Республики Казахстан filed Critical Ргкп Научно-Исследовательский Институт Кардиологии И Внутренних Болезней Министерства Здравоохранения Республики Казахстан
Priority to EA200800281A priority Critical patent/EA015399B1/en
Publication of EA200800281A1 publication Critical patent/EA200800281A1/en
Publication of EA015399B1 publication Critical patent/EA015399B1/en

Links

Abstract

Изобретение относится к области медицины, а именно к кардиологии. Средство заключается в применении мицеллярного трансдермального препарата интерферона альфа у животных с экспериментальным миокардитом в дозе 25 мг/кг 1 раз в день в течение 14 дней, когда регистрируется повышение фракции выброса миокарда на 23,3%. Кроме того, при воздействии мицеллярной формы препарата интерферона альфа у животных с миокардитом улучшение морфологической картины миокарда.The invention relates to medicine, namely cardiology. The remedy consists in the use of the micellar transdermal drug interferon alpha in animals with experimental myocarditis at a dose of 25 mg / kg once a day for 14 days, when an increase in the myocardial ejection fraction by 23.3% is recorded. In addition, when exposed to the micellar form of the drug interferon alpha in animals with myocarditis, the morphological picture of the myocardium is improved.

EA200800281A 2007-11-15 2007-11-15 Method for the treatment of viral myocarditis EA015399B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200800281A EA015399B1 (en) 2007-11-15 2007-11-15 Method for the treatment of viral myocarditis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200800281A EA015399B1 (en) 2007-11-15 2007-11-15 Method for the treatment of viral myocarditis

Publications (2)

Publication Number Publication Date
EA200800281A1 true EA200800281A1 (en) 2009-06-30
EA015399B1 EA015399B1 (en) 2011-08-30

Family

ID=40933239

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800281A EA015399B1 (en) 2007-11-15 2007-11-15 Method for the treatment of viral myocarditis

Country Status (1)

Country Link
EA (1) EA015399B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation

Also Published As

Publication number Publication date
EA015399B1 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
ES2528650T3 (en) Transdermal therapeutic system comprising buprenorphine
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
RU2015132860A (en) LONG-TERM INSULIN COMPOSITIONS
PE20130396A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE DEUTERATED, SALTS AND USES OF THE SAME
ES2916604T1 (en) Nrf2 Detection Assays and Related Methods and Compositions
NZ743706A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
AR047993A1 (en) PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES
UA107578C2 (en) COMBINED DIABETES THERAPY
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
RU2013111077A (en) DIPEPTID MEDICINE, ITS APPLICATION AND MEDICINE
AR062792A1 (en) AZETIDINONE DERIVATIVES AND METHODS OF USE OF THESE
CY1111934T1 (en) STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING FESOTERODIN
FR2983409B1 (en) COMPRESSOR CAPABLE OF COMBATTING INJECTION MISTAKE
AR086356A1 (en) PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF PATIENTS WHO HAVE TYPE 2 DIABETES
ATE387910T1 (en) METHOD FOR IMPROVING THE BIOAVAILABILITY OF OSPEMIFENE
UA109421C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS
NZ595767A (en) Composition for the treatment of prostate cancer
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
ES2527623T3 (en) Iminoazúcares for use in the treatment of filovirus diseases
JP2013537240A5 (en)
AR073265A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
ES2673406T3 (en) Alpha-derivatives of cis-monounsaturated fatty acids for use as medications in the treatment of diabetes
EA201270573A1 (en) GRANULATED IN THE MELT ZINCALZETTE
JP2017516842A5 (en)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU